The Expense Of Diabetes: Is It Worth It? Eli Lilly & Co. (LLY), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT)

Page 1 of 2

With studies showing 33% of Americans with diabetes or pre-diabetes, it is obvious that the industry should be booming. Like most fields there is stiff competition in the industry. I recently wrote a piece explaining why it appears these companies should be good investments. Since then earnings have been released, so let’s see how they stack up now.

Lilly calls active as shares soar; Put spreads constructed on Verizon, AT&TEli Lilly & Co. (NYSE:LLY) and Novo Nordisk A/S (ADR) (NYSE:NVO) are the two largest insulin companies in the world.  They are slightly more specific than other companies because their market is narrower. Generally speaking, type one diabetics need insulin and most type two diabetics don’t (although more and more type two’s are using insulin). Although only one in three hundred American’s are type one diabetics, that is nearly twice as much as it was thirty years ago. The rates of type one diabetics are increasing globally at three percent every year.

Lilly and Novo Nordisk posted different results in their Q4 results. Although Lilly posted better than expected earnings, revenues did decline by 1%. The patent expiry of Zyprexa led to the decrease, but other products such as Cymbalta, Forteo and Alimta nearly made the loss a wash. Novo Nordisk showed a solid 18% increase in sales growth, and net profits also increased by 25%.

Lilly forecasts earnings to increase 15% in 2013. Novo Nordisk expects to see around 10% growth in sales and operating profits.

Abbott Laboratories (NYSE:ABT)
is a test strip manufacturer that recently spun off a new company coined AbbVie Inc (NYSE:ABBV) which virtually split Abbott Laboratories (NYSE:ABT) in half. Abbott remained the diabetic manufacturer.  Despite this spin off, Abbott posted solid numbers this past quarter as well as some expected declines. Although the company posted a 46% decrease in net income for the quarter, net sales increased by 4%. For the year, net income increased by over 26%, or $1.23 billion dollars. Net sales increased by over $1 billion as well.

Abbott’s CEO Miles White had this to say, “In 2012, we achieved a significant milestone in Abbott’s 125-year history with the creation of AbbVie while delivering another year of strong results. Abbott’s mix of diversified healthcare businesses and pipeline is favorably aligned with key healthcare and emerging market trends and well positioned to deliver top-tier growth in 2013.”

With over 40% of Johnson & Johnson (NYSE:JNJ)’s revenue acquired from medical devices/diagnostics, diabetes is again playing a major role in a company’s success. In Q4, medical devices/diagnostics sales rose to $7.38 billion dollars in the fourth quarter, an increase of 13.7%. Johnson & Johnson (NYSE:JNJ) expects to increase revenues this year by 7%, bringing the expected total to around $72 billion. This past quarter, the company’s sales increased 8% with the Synthes deal contributing 5.6% of that growth. It becomes obvious when looking at these numbers how significant of a role medical devices/diagnostics really are to Johnson and Johnson.

The last company we will look at today is the clear insulin pump market leader. Diabetes directly accounts for 10% of Medtronic, Inc. (NYSE:MDT)’s revenues. Indirectly (mainly complications from the disease) Diabetes accounts for 40% of the company’s revenues. However, I don’t want to talk about earnings or diabetes with this company.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!